Back

Acoramidis has a beneficial effect compared with placebo on change from baseline in NAC ATTR stage at month 30 in patients with ATTR-CM: results from the ATTRibute-CM study

29 August 2025 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Cardiac amyloidosis (1) Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Julian Gillmore

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Miss P. Domenech (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Assistant Professor A. Zaroui (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Doctor A. Martins (Leiria, PT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Cardiac amyloidosis (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Acoramidis-mediated improvement in NT-proBNP at month 30 compared with placebo in patients with ATTR-CM: results from the ATTRibute-CM study
thumbnail
Congress Presentation
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources